A decades-old compound may point to a new way of treating obesity by making the body burn more energy rather than simply reducing appetite. In mice, TOFA increased energy use by as much as 18%, reduced body fat without significant muscle loss, and improved blood sugar, triglycerides, and fatty liver disease. It also produced stronger results when combined with GLP-1 drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound.
And
Maybe I missed it. Did the mice lose weight? Or did they increase calorie intake to make up for increased utilization?
Brief Summary
Researchers at UC Berkeley and collaborating institutions repurposed a forgotten 1970s-era compound, 5-tetradecyloxy-2-furoic acid (TOFA), and showed it does two things at once in mice: it blocks the enzymes that build new fat (ACC1 and ACC2) and it partially activates the PPAR alpha and PPAR delta nuclear receptors that govern fat burning and energy expenditure. In diet-induced obese mice this combination produced roughly 18 percent body weight loss over four weeks, entirely from fat mass with lean mass preserved, without any reduction in food intake. It also cut liver fat, serum triglycerides, LDL cholesterol and fasting insulin, reduced liver inflammation and fibrosis in two separate models of fatty liver disease, and raised whole-body energy expenditure by about 18 percent. Critically, TOFA avoided the hypertriglyceridemia that has derailed every previous ACC inhibitor. When combined with semaglutide or tirzepatide the effects were additive, and after treatment stopped, TOFA-treated mice did not rebound the way semaglutide-treated mice did. No human data exist.
For fifty years, drug developers have wanted to switch off acetyl-CoA carboxylase, the enzyme that converts sugar into fat. Every attempt has run into the same wall. Block the enzyme and the liver, deprived of its usual outlet, compensates by pumping triglycerides into the bloodstream instead. Firsocostat, the most advanced clinical candidate, does exactly this, which is why it has never made it as a standalone therapy.
A team led by Anders Näär at UC Berkeley went back to a compound that chemists had characterised in the 1970s and then largely abandoned. TOFA is a fatty acid look-alike. Once inside a cell it is converted to TOFyl-CoA, a form that shuts down both ACC enzymes at sub-nanomolar concentrations. But the team found something the original chemists missed. Because TOFA structurally mimics a long-chain fatty acid, it also binds and partially activates PPAR alpha and PPAR delta, the nuclear receptors that act as master switches for fat burning, mitochondrial output and lipid clearance. One molecule, two mechanisms, pulling in the same direction.
The consequence is a drug that behaves unlike anything in its class. Obese mice given TOFA by mouth lost about 18 percent of their body weight in four weeks. They ate exactly as much as untreated mice. What changed was the burn rate: energy expenditure rose roughly 18 percent, and the weight came off fat while muscle was preserved. Liver fat fell by more than half. Blood triglycerides went down rather than up, resolving the class problem. In two independent mouse models of fatty liver disease the drug reduced inflammation, oxidative damage and collagen deposition.
The most commercially interesting result concerns the GLP-1 drugs. Semaglutide and tirzepatide work by suppressing appetite; TOFA works by raising expenditure. Given together, the effects stacked. And when the drugs were withdrawn, semaglutide mice regained weight immediately while TOFA mice held their new weight for weeks.
The caution is unavoidable. This is entirely mouse and cell work, all in male animals, with no lifespan or long-term safety data, and no human has ever taken this compound. The mechanism is elegant and the effect sizes are large, but the graveyard of obesity drugs is full of molecules that looked exactly this good in mice.
Insights For individuals tracking metabolic optimization and longevity protocols, this study delivers critical physiological insights:
The effect sizes in mice are genuinely large. Statisticians measure separation between two groups with Cohen’s d, where 0.8 counts as a large effect. Body weight reduction here came out at about d = 2.8, fat mass at about d = 2.7, and fasting insulin at about d = 2.1. In plain terms, a d of 2.8 means that if you picked one treated mouse and one control mouse at random, the treated one would be lighter about 98 percent of the time. The groups barely overlap. Liver triglycerides fell with d of roughly 1.9 in obese mice and 2.9 in the fatty liver model, again near total separation.
Context/Source
Study Design Specifications
Biomarker Data (Effect Size Extraction) The primary physiological and biomarker shifts recorded across the cohorts demonstrate exceptionally large standardized effect sizes:
Mechanistic Deep Dive
Novelty
The Translational Protocol
Human Equivalent Dose Calculation
Human equivalent dose (HED) is calculated using body surface area normalization based on standard FDA conversion guidance:
HED (mg/kg) = Animal Dose (mg/kg) * (Animal Km / Human Km)
Using standard reference values (mouse Km = 3, human Km = 37), the conversion factor is 3 / 37 = 0.08108.
Low and Maintenance Dose: 62.5 mg/kg twice daily (125 mg/kg/day)
Calculation: 125 mg/kg/day * (3 / 37) = 10.14 mg/kg/day
70 kg Human Dose: 10.14 mg/kg * 70 kg = 709.8 mg/day (approximately 710 mg/day)
Standard High Dose: 200 mg/kg/day
Calculation: 200 mg/kg/day * (3 / 37) = 16.22 mg/kg/day
70 kg Human Dose: 16.22 mg/kg * 70 kg = 1,135.4 mg/day (approximately 1.14 g/day)
Maximum Single Loading Dose: 250 mg/kg/day
Calculation: 250 mg/kg/day * (3 / 37) = 20.27 mg/kg/day
70 kg Human Dose: 20.27 mg/kg * 70 kg = 1,418.9 mg/day (approximately 1.42 g/day)
Pharmacokinetics and Pharmacodynamics
Preclinical Absorption and Cmax: A single oral gavage of 250 mg/kg in mice produced a peak plasma concentration (Cmax) exceeding 10,000 ng/mL (approximately 30.8 uM) within 30 to 60 minutes. This exceeds the in vitro IC50 values for ACC1 (0.236 uM as TOFyl-CoA) and ACC2 (0.160 uM as TOFyl-CoA), as well as the EC50 values for human PPAR-alpha (2.095 uM) and human PPAR-delta (0.594 uM).
Elimination Half-Life: In mice, oral administration demonstrated a sustained elimination half-life exceeding 6 hours, maintaining measurable plasma concentrations at 24 hours post-dose.
Human Pharmacokinetic Profile: Safety Data Absent.
Safety and Toxicity Profile
Acute Toxicity (LD50): Oral LD50 in rats is greater than 5,000 mg/kg (> 5.0 g/kg).
Chronic Toxicity and NOAEL: Six months of daily administration in rats produced no lethality or overt systemic failure at hypolipidemic doses, though classic rodent-specific hepatic peroxisome proliferation was observed.
Phase I Clinical Safety Profile: Safety Data Absent.
Human CYP450 Interactions: Safety Data Absent.
Hepatic and Renal Biomarkers: Murine models showed significant reductions in serum ALT and AST, reduced hepatic hydrogen peroxide oxidative stress, and no elevations in blood urea nitrogen or creatinine.
Biomarker Verification Panel
| Biomarker | Target / Biological Mechanism | Expected Physiological Direction |
|---|---|---|
| Serum FGF21 | Hepatic PPAR-alpha activation | 4-fold to 6-fold increase |
| Serum Triglycerides and VLDL-C | ACC inhibition and PPAR-mediated lipid clearance | 40% to 55% reduction |
| Fasting Insulin and HOMA-IR | Reversal of systemic insulin resistance | Greater than 70% reduction |
| Hepatic Steatosis (MRI-PDFF / CAP) | De novo lipogenesis suppression | Greater than 50% relative reduction |
| Serum ALT and AST | Resolution of liver necroinflammation | 30% to 50% reduction toward baseline |
| Cellular Malonyl-CoA | Direct ACC1 and ACC2 enzymatic inhibition | Significant suppression in target tissue |
| Transcriptional Markers (PDK4, CPT1A) | PPAR-alpha and PPAR-delta target engagement | Coordinated mRNA upregulation |
Feasibility and ROI
Sourcing Classification: Research Chemical and Analytical Reference Standard only (CAS 54857-86-2). It is not approved as a dietary supplement or prescription pharmaceutical in any jurisdiction.
Catalog Unit Cost: Biochemical suppliers list research-grade TOFA at approximately $40 to $70 per 5 to 10 mg, and $255 to $470 per 50 to 100 mg.
Estimated Monthly Cost for Human Equivalent Dose: At an adult target dose of 1,000 mg daily (30 g per month), purchasing reference-standard material equates to $135,000 to $195,000 USD monthly. Bulk custom non-GMP chemical synthesis could theoretically lower raw powder costs to $90 to $300 monthly, but introduces severe risks of residual solvent toxicity, heavy metal contamination, and lack of analytical certification.
Return on Investment: Poor. Self-administration carries extreme clinical and financial risks given the lack of human safety data and the widespread clinical availability of approved metabolic modulators.
1. Does an 18% increase in whole-body energy expenditure cause cardiovascular strain or hyperthermia?
Preclinical indirect calorimetry demonstrated an 18% elevation in energy expenditure with no change in core body temperature (p = 0.971) and no increase in physical activity. The thermogenic demand is distributed across hepatic and muscular mitochondrial uncoupling rather than central adrenergic stimulation. However, clinical evaluation in humans must verify that resting heart rate, blood pressure, and myocardial oxygen demand remain stable during chronic treatment.
2. How much of TOFA’s hepatic efficacy relies on rodent-specific PPAR-alpha biology?
Rodents express higher basal hepatic PPAR-alpha than humans and undergo extensive peroxisome proliferation when stimulated. However, TOFA was confirmed to directly bind purified human PPAR-alpha (EC50 = 2.095 uM) and human PPAR-delta (EC50 = 0.594 uM), and induced PPAR target genes in human HepG2 and Huh7 hepatoma cells. While the absolute magnitude of fatty acid oxidation may be lower in human liver, the underlying transcriptional mechanism is active in human tissue.
3. Is there a risk of myocardial toxicity or impaired cardiac energetics from ACC2 inhibition?
Safety Data Absent. The myocardium relies heavily on mitochondrial fatty acid beta-oxidation. While ACC2 inhibition relieves malonyl-CoA suppression on CPT-1 to facilitate fatty acid entry, persistent uncoupling and altered substrate utilization in cardiomyocytes could theoretically affect cardiac efficiency under ischemic conditions. Comprehensive echocardiography and cardiac safety studies are required.
4. Why was lifespan not evaluated, and could chronic uncoupling impact longevity?
The study was restricted to acute and sub-chronic metabolic disease models (1 to 6 weeks duration). Reversing visceral adiposity, hepatic steatosis, and hyperinsulinemia addresses primary drivers of cardiometabolic mortality. However, direct longevity outcomes remain untested. In standard model organisms, chronic ACC inhibition can have divergent effects depending on dietary lipid composition. Long-term rodent lifespan studies are needed to evaluate late-life frailty and survival curves.
5. Why did co-administering Firsocostat and Elafibranor fail to match TOFA’s monotherapy efficacy?
In head-to-head mouse trials, co-administering separate ACC and PPAR drugs did not reproduce TOFA’s magnitude of weight reduction and glycemic control. Intracellular conversion of TOFA into TOFyl-CoA ensures stoichiometric ACC inhibition alongside direct PPAR binding within the exact same target cell. Separate pharmaceuticals display divergent pharmacokinetic curves, tissue distribution, and cellular clearance, failing to achieve identical intracellular harmony.
6. What is the physiological basis for lean muscle preservation during weight loss?
Standard caloric restriction and incretin monotherapies cause 20% to 40% of total weight loss to come from lean body mass. TOFA preserved lean muscle mass (25.1 g control vs. 23.8 g TOFA, p = 0.053) and maintained treadmill endurance. Because food intake remains unaffected, systemic amino acid starvation is avoided. Simultaneously, PPAR-delta activation in skeletal muscle supports fatty acid oxidation and protects structural protein from catabolic breakdown.
7. How should clinical protocols manage cachexia risks seen with high-dose incretin combinations?
Combining full-dose TOFA with Tirzepatide produced precipitous weight loss exceeding animal welfare thresholds, requiring a 50% dose reduction by Day 10. Translating this combination to humans requires conservative dose titration: pairing low-dose incretin therapy with low-dose metabolic accelerators to achieve steady fat loss while avoiding rapid adipose depletion, electrolyte disturbances, or gallstone formation.
8. Why did TOFA-treated mice avoid the rapid weight regain observed after semaglutide withdrawal?
Semaglutide withdrawal led to immediate hyperphagia, where animals consumed excessive calories and rapidly regained fat mass. TOFA never suppressed food intake during treatment, meaning hypothalamic appetite circuits were not sensitized upon drug cessation. Additionally, cleared hepatic fat and restored insulin sensitivity maintained a higher resting metabolic rate during the post-treatment washout period.
9. What are the limitations of excluding female mice from this research?
Female rodents were excluded because endogenous estrogens protect against diet-induced hepatic steatosis and insulin resistance via suppression of white adipose lipolysis. This limits the generalizability of the findings. Because estrogen receptor signaling interacts directly with PPAR networks, dedicated trials in female, ovariectomized, and post-menopausal models are essential to confirm cross-sex efficacy.
10. Could the active metabolite TOFyl-CoA cause off-target inhibition of other acyl-CoA enzymes?
TOFyl-CoA is a synthetic fatty acyl-CoA analog. While it demonstrates sub-micromolar potency against ACC1 and ACC2, structurally similar metabolites can interact with other lipid-metabolizing enzymes such as Fatty Acid Synthase (FASN), Diacylglycerol Acyltransferases (DGAT), or Acyl-CoA Synthetases (ACSL). Proteome-wide selectivity profiling is necessary to map its complete biochemical interactome.
Interaction Check: Common Longevity Stacks
| Compound Class / Molecule | Interaction Risk | Clinical & Mechanistic Assessment |
|---|---|---|
| Rapamycin (mTORC1 Inhibitor) | Low / Favorable Synergy | Rapamycin can induce secondary dyslipidemia and hypertriglyceridemia. TOFA counteracts hypertriglyceridemia through ACC inhibition and PPAR activation, while complementing rapamycin-mediated autophagy via hepatic mitophagy upregulation (Pink1, Prkn, Bnip3). |
| SGLT2 Inhibitors (Empagliflozin, Dapagliflozin) | Moderate Risk (Ketosis Monitoring) | SGLT2 inhibitors induce glycosuria and shift whole-body fuel selection toward lipid oxidation and ketogenesis. TOFA strongly upregulates hepatic beta-oxidation. Co-administration could accelerate ketone body production, raising the theoretical risk of euglycemic ketoacidosis under prolonged fasting. |
| Metformin (AMPK Activator) | Low / Favorable Synergy | Metformin stimulates AMPK, which phosphorylates and inactivates ACC1 and ACC2. TOFA directly inhibits ACC carboxyltransferase activity and activates PPAR-alpha/delta. Both compounds converge to suppress hepatic gluconeogenesis, lower fasting insulin, and resolve steatosis. |
| Acarbose (Alpha-Glucosidase Inhibitor) | Low / Neutral | Acarbose acts locally in the intestinal brush border to slow carbohydrate digestion. It does not alter systemic lipid oxidation or PPAR transcription, presenting no known pharmacokinetic or mechanistic conflict. |
| 17-alpha Estradiol (Metabolic Modulator) | Low / Favorable Synergy | 17-alpha estradiol acts via non-feminizing estrogen receptor pathways to reduce male visceral adiposity and hepatic inflammation. Combining it with TOFA targets metabolic dysfunction through distinct, non-competing enzymatic and transcriptional mechanisms. |
| PDE5 Inhibitors (Tadalafil, Sildenafil) | Low / Neutral | PDE5 inhibitors elevate intracellular cGMP to enhance endothelial function and tissue perfusion. There is no known metabolic clearance conflict with furoic acid derivatives; cardiovascular benefits remain independent. |